Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...
These nanoparticles exhibit tunable size, non-toxic profiles and ... to the United States Patent and Trademark Office, and is currently under review. "Molecularly targeted therapies are effective ...
Some of the trademarks that appear in this release or otherwise used by H&P include FlexRig, which may be registered or trademarked in the United States and other jurisdictions. (1) Select items are ...
The championship match showcased Gauff’s remarkable resilience as she overcame Chinese competitor Zheng Qinwen in an intense three-set contest. After dropping the first set 3-6, Gauff mounted a ...
- Contributing to Higher Efficiency in Automotive Electric Compressors and Inverters for Industrial Equipment - KYOTO, Japan, Nov. 12, 2024 /PRNewswire/ -- ROHM Co., Ltd. has developed ...
Book-to-bill above 1 and sales organic growth around 5% aEBIT margin around 6.5% Free Cash Flow within the range €300 million to €500 million 13 November 2024 - In the first half of fiscal year ...
Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected ...
Reshmi Bennett: ‘The best way to use a hand mixer is to always start ‘low and slow.’ Introduce ingredients gradually, ...
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences,” or the "Company” ...
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback